ATE500276T1 - Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung - Google Patents

Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Info

Publication number
ATE500276T1
ATE500276T1 AT05855920T AT05855920T ATE500276T1 AT E500276 T1 ATE500276 T1 AT E500276T1 AT 05855920 T AT05855920 T AT 05855920T AT 05855920 T AT05855920 T AT 05855920T AT E500276 T1 ATE500276 T1 AT E500276T1
Authority
AT
Austria
Prior art keywords
humanized col
antibodies
disclosed
col
residies
Prior art date
Application number
AT05855920T
Other languages
English (en)
Inventor
Syed Kashmiri
Jeffrey Schlom
Eduardo Padlan
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE500276T1 publication Critical patent/ATE500276T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05855920T 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung ATE500276T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64067204P 2004-12-30 2004-12-30
PCT/US2005/047431 WO2006074071A1 (en) 2004-12-30 2005-12-30 Framework residue substituted humanized col-1 antibodies and their use

Publications (1)

Publication Number Publication Date
ATE500276T1 true ATE500276T1 (de) 2011-03-15

Family

ID=36216923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05855920T ATE500276T1 (de) 2004-12-30 2005-12-30 Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung

Country Status (7)

Country Link
US (2) US7855276B2 (de)
EP (1) EP1833850B9 (de)
AT (1) ATE500276T1 (de)
AU (1) AU2005322869B2 (de)
CA (1) CA2593693A1 (de)
DE (1) DE602005026706D1 (de)
WO (1) WO2006074071A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334701A4 (de) 2008-10-16 2014-01-08 Univ Pittsburgh Vollständig menschliche antikörper gegen mit melanomen von hohem molekulargewicht assoziierte antigene und verwendungen davon
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
US8497354B2 (en) 2010-06-16 2013-07-30 University of Pittsburgh—of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US8771687B2 (en) 2010-12-02 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds GRP94
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
EP3452508A1 (de) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antikörper zur erkennung von tau
EP3452507B1 (de) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau-immuntherapie
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
SG11201910066QA (en) * 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN113393899A (zh) * 2021-05-26 2021-09-14 江苏普瑞康生物医药科技有限公司 基于动态规划的抗体人源化的方法与装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
AU766149B2 (en) 1998-10-31 2003-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variants of humanized anti-carcinoma monoclonal antibody CC49
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
WO2004022717A2 (en) * 2002-09-05 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME

Also Published As

Publication number Publication date
WO2006074071A1 (en) 2006-07-13
US7855276B2 (en) 2010-12-21
WO2006074071A8 (en) 2006-09-14
AU2005322869A1 (en) 2006-07-13
EP1833850B1 (de) 2011-03-02
EP1833850A1 (de) 2007-09-19
US20110053264A1 (en) 2011-03-03
US20080274055A1 (en) 2008-11-06
AU2005322869B2 (en) 2011-05-12
DE602005026706D1 (de) 2011-04-14
EP1833850B9 (de) 2011-05-18
CA2593693A1 (en) 2006-07-13
US8828717B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200807263A2 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
JP2017508475A5 (de)
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
NO20090462L (no) Anti-NKG2A-antistoffer og anvendelser derav
RS52484B (en) CD40 ANTIBODIES
WO2007092939A8 (en) Antigenic gm-csf peptides and antibodies to gm-csf
EP1603949B8 (de) Antikörper gegen il21-rezeptor und deren verwendung
MX343879B (es) Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
SG151284A1 (en) Antibodies against ccr5 and uses thereof
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
SG170793A1 (en) Anti-mn antibodies and methods of using same
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE60334364D1 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
IN2012DN05101A (de)
EA200701092A1 (ru) Антигенные эпитопы интерлейкина-21, связанные с ними антитела и их применение в медицине
EP2192132A3 (de) Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties